MET and prostate carcinoma: To investigate the prevalence of the METΔ7–8 mutation further, we performed the exon 6–9 PCR on cDNA, generated from a series of gliomas (n = 102) and a number of other tumor types in which MET has been suggested to play an important role (castration-resistant prostate carcinomas, n = 43; Ewing sarcoma, n = 21; rhabdomyosarcoma, n = 22) [24, 28].